Big boost for India, prevention of typhoid turns easier, Bharat Biotech vaccine gets WHO nod

By: |
New Delhi | January 4, 2018 12:24 PM

The new vaccine was found to have given a longer immunity from typhoid than older vaccines and it required fewer doses for childhood immunisation.

Bharat Biotech said that the World Health Organisation (WHO) has pre-qualified its typhoid conjugate vaccine.

Bharat Biotech Ltd (BBL), a Hyderabad-based vaccine maker, on Wednesday, said that the World Health Organisation (WHO) has pre-qualified its typhoid conjugate vaccine. The new vaccine was found to have given a longer immunity from typhoid than older vaccines and it required fewer doses for childhood immunisation. The pre-qualification by WHO allows for the sale of the vaccines to UN agencies such as UNICEF and GAVI. Typbar TCV is reportedly the world’s first typhoid vaccine clinically proven for use on recipients who can be as young as six months. A single dose offers 87 per cent protective efficacy against typhoid, which sickened 12 million people and killed 130,000 worldwide in 2016.

As per reports, Bharat Biotech spent about Rs 150 crores from its own pockets for the vaccine and received $40 million in grants from various universities.

It has been found in the clinical trials that the use of the vaccine could help in curbing the frequent use of antibiotics for treatment of presumed typhoid fever. Though the vaccine is approved for use in India, it is not yet a part of India’s Universal Immunisation Programme. Its retail price in India is Rs 1,500.

Typhoid fever is caused by food and water contaminated by Salmonella Typhi (S. Typhi) bacteria. The symptoms of the disease include fever, headache, nausea, loss of appetite, constipation and sometimes diarrhoea. According to the World Health Organisation, typhoid affects about 21 million people per year and kills around 222,000.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1‘Convince farmers on MSP, not me’, Amarinder Singh hits back at Haryana CM
2Ratan Tata pens heartfelt note on Mumbai on 26/11 anniversary
3‘Only tweeting, running away from talks’, Khattar slams Amarinder for criticising Haryana’s handling of farmers’ march